New data show Gilenya® (fingolimod) reduced brain volume loss by one third and confirm link between brain volume loss and MS disability
Novartis has announced new data indicating that continued treatment with Gilenya® (fingolimod) led to a reduction in brain volume loss in people with relapsing remitting multiple sclerosis (RRMS), and was associated with a higher proportion of people remaining free of disability progression compared to placebo.1 These data were presented at the 29th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) in Copenhagen, Denmark... (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - October 7, 2013 Category: Consumer Health News Tags: Multiple Sclerosis Source Type: news

Novartis' Gilenya® long-term efficacy on reducing brain volume loss and real-world relapse rates in MS
New data showing the benefits of Gilenya® (fingolimod) on patient outcomes in multiple sclerosis (MS) will be presented at the 29th Congress of the European Committee for Research and Treatment in Multiple Sclerosis (ECTRIMS) in Copenhagen, Denmark, adding to the growing evidence base for Gilenya in both clinical trial and real-world settings. (Source: Pharmacy Europe)
Source: Pharmacy Europe - September 25, 2013 Category: Drugs & Pharmacology Authors: ebercott Tags: *** Editor's Pick Neurology Latest News Source Type: news

FDA investigate brain infection in patient receiving Novartis’s MS drug
The case of a patient that has developed a rare and dangerous brain infection while taking Novartis's multiple sclerosis (MS) drug Gilenya is being investigated by the US Food and Drug Administration (FDA). (Source: Pharmaceutical Technology)
Source: Pharmaceutical Technology - August 29, 2013 Category: Pharmaceuticals Source Type: news

Morning Break: PML and Fingolimod; Humor on Twitter
(MedPage Today) -- Health news and commentary from around the Web, gathered by the MedPage Today staff. (Source: MedPage Today Psychiatry)
Source: MedPage Today Psychiatry - August 29, 2013 Category: Psychiatry Source Type: news

FDA Investigating a Case of PML With GilenyaFDA Investigating a Case of PML With Gilenya
A safety announcement from the FDA today outlines a case of PML in a patient taking fingolimod not previously treated with natalizumab. News Alerts (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - August 29, 2013 Category: Consumer Health News Tags: Neurology & Neurosurgery News Alert Source Type: news

US FDA probes brain infection in patient on Novartis's MS drug
(Reuters) - The U.S. Food and Drug Administration said it was investigating a case of a rare and serious brain infection that developed in a patient in Europe, who was being treated with Novartis's multiple sclerosis drug, Gilenya. (Source: Reuters: Health)
Source: Reuters: Health - August 29, 2013 Category: Consumer Health News Tags: healthNews Source Type: news

FDA Warns of PML Case With Gilenya
(MedPage Today) -- SILVER SPRING, Md. -- A patient being treated for multiple sclerosis and who had no history of using natalizumab (Tysabri) developed progressive multifocal leukoencephalopathy (PML) while taking fingolimod (Gilenya), the FDA said. (Source: MedPage Today Public Health)
Source: MedPage Today Public Health - August 29, 2013 Category: American Health Source Type: news

Gilenya (fingolimod) - Drug Safety Communication: Investigating Rare Brain Infection
Patient has developed a rare and serious brain infection after taking the drug. (Source: FDA MedWatch)
Source: FDA MedWatch - August 29, 2013 Category: American Health Source Type: news

Fingolimod and PML
The US Federal Drug Agency (FDA) is investigating the case of a person on fingolimod who was diagnosed with PML. The investigation is looking at whether the infection is due to fingolimod or to previous treatment received. This is the same case as was first reported on 30 July. Reuters National MS Society (USA) Medpage Today Fingolimod (Gilenya) - A to Z of MS Progressive multifocal leukoencephalopathy - A to Z of MS (Source: Multiple Sclerosis Trust)
Source: Multiple Sclerosis Trust - August 28, 2013 Category: Neurology Source Type: news

PML Case Seen in Patient on Gilenya
(MedPage Today) -- A patient taking the oral multiple sclerosis drug fingolimod (Gilenya) for 7 months developed progressive multifocal leukoencephalopathy (PML), according to Novartis, the drug's manufacturer. (Source: MedPage Today Infectious Disease)
Source: MedPage Today Infectious Disease - July 31, 2013 Category: Infectious Diseases Source Type: news

Patient Taking MS Pill Gilenya Developed PMLPatient Taking MS Pill Gilenya Developed PML
Novartis said it had been informed of a case of progressive multifocal leukoencephalopathy (PML) in a patient who had been taking the oral multiple sclerosis drug fingolimod (Gilenya) for seven months. Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - July 30, 2013 Category: Consumer Health News Tags: Neurology & Neurosurgery News Source Type: news

Patient taking Novartis MS pill developed rare disease
ZURICH (Reuters) - A patient taking Novartis' multiple sclerosis pill Gilenya developed a rare and potentially fatal viral disease, the Swiss drugmaker said on Tuesday, an unexpected setback as it faces growing competition from new oral treatments. (Source: Reuters: Health)
Source: Reuters: Health - July 30, 2013 Category: Consumer Health News Tags: healthNews Source Type: news

Case of PML seen in person taking fingolimod
A woman taking fingolimod developed progressive multifocal leukoencephalopathy (PML) after 7 months treatment. Manufacturer (Novartis) is working with the her medical team to understand all possible contributing factors, given several atypical features of the case. Reuters Medpage Today Fingolimod (Gilenya) Progressive multifocal leukoencephalopathy (Source: Multiple Sclerosis Trust)
Source: Multiple Sclerosis Trust - July 29, 2013 Category: Neurology Source Type: news

Fingolimod Therapy for Multiple SclerosisFingolimod Therapy for Multiple Sclerosis
The use of fingolimod therapy for multiple sclerosis has been limited by concerns for its safety, especially regarding cardiac effects. What do you need to know to prescribe and monitor it safely? Seminars in Neurology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - July 11, 2013 Category: Consumer Health News Tags: Neurology & Neurosurgery Journal Article Source Type: news

Siponimod for relapsing MS
A study for siponimod, a drug that works in a similar way to fingolimod, measured the number of new lesions seen on MRI scans in 297 people with relapsing remitting MS. A higher dose was associated with fewer lesions, but the 2mg dose showed best balance between effectiveness and side effects and will now go on to a phase III study. The drug is also being investigated in secondary progressive MS. MS Research Australia Drug development process (Source: Multiple Sclerosis Trust)
Source: Multiple Sclerosis Trust - July 2, 2013 Category: Neurology Source Type: news